ARQT Earnings & Financial Statements
Arcutis Biotherapeutics, Inc.
$26.41
+$0.32(+1.23%)
47
Overall
20
Value
66
Tech
57
Quality
Market Cap
$3.32B
Volume
1.62M
52W Range
$19.30 - $31.77
Target Price
$37.00
ARQT earnings and financial statements: Arcutis Biotherapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ARQT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $376.07M | $196.54M | $59.61M | $3.69M | - |
| Cost of revenue | $36.70M | $19.13M | $4.99M | $754.0K | - |
| Operating income | -$12.23M | -$128.40M | -$241.10M | -$301.63M | -$206.53M |
| EBITDA | $1.78M | -$110.27M | -$227.41M | -$306.83M | -$218.94M |
| Net income | -$16.14M | -$140.04M | -$262.14M | -$311.46M | -$206.36M |
| EPS (diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $432.97M | $348.89M | $341.37M | $449.27M | $408.15M |
| Total liabilities | $243.49M | $191.35M | $252.70M | $239.69M | $110.47M |
| Shareholders’ equity | $189.48M | $157.54M | $88.67M | $209.58M | $297.68M |
| Cash and equivalents | $42.91M | $71.33M | $88.40M | $53.64M | $96.45M |
| Long-term debt | $113.22M | $109.77M | $205.18M | $201.89M | $77.12M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.63M | -$112.16M | -$247.06M | -$257.71M | -$174.63M |
| Capital expenditure | -$10.69M | -$5.14M | -$428.0K | -$23.28M | -$995.0K |
| Free cash flow | -$16.31M | -$117.30M | -$247.49M | -$265.55M | -$175.62M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARQT | $26.41 | +1.2% | 1.62M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arcutis Biotherapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW